Riskpilot← Back to searchSign inGet full accessLinio Biotech Oy
OYActiveY-tunnus 2871201-8Tehtaankatu 2729-AResearch and experimental development on natural sciences and engineering · NACE 7210Est. 201713 employeeswww.linio-biotech.com
Revenue 2024
EUR 207K
+227% vs 2023
EBITDA margin
-468.0%
+19% vs 2023
Equity ratio
92.8%
Financial strength
Net profit 2024
EUR -1M
+19% vs 2023
| Revenue | EUR 207K | +227% |
| EBITDA | EUR -968K | +19% |
| Net profit | EUR -1M | +19% |
| Total assets | EUR 5,2M | +41% |
| Equity | EUR 4,8M | +42% |
| Employees | 13 | — |
Legal name
Linio Biotech Oy
Y-tunnus number
2871201-8
Legal form
Osakeyhtiö
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. marraskuuta 2017
Share capital
EUR 2 500
Employees
13 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on lääketieteellisten ja kosmeettisten hoitotuotteiden kehittäminen, tutkiminen ja kaupallistaminen sekä aineettomien oikeuksien ja lisenssien hallinnointi, ostaminen ja myyminen. Yhtiö toimii lisäksi kudoslaitoksena, jonka tehtävänä on ihmiskudoksen hankinta, testaus, talteenotto, säilöminen, säilytys, käsittely ja jakelu. Yhtiö voi myös harjoittaa irtaimen ja kiinteän omaisuuden kauppaa, omistusta ja vuokraamista sekä sijoitustoimintaa.
Address
Tehtaankatu 2729-A
Phone
+358503878119
Email
info@linio-biotech.com
Website
www.linio-biotech.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 63 | 207 |
| Staff expenses | −11 | −121 | −491 | −860 | −1 073 |
| EBITDA | −5 | −251 | −811 | −1 196 | −968 |
| Depreciation & amort. | — | −18 | −18 | −63 | −95 |
| EBIT | −5 | −269 | −830 | −1 259 | −1 063 |
| Net financials | −0 | −207 | 2 | 1 | 47 |
| Profit before tax | −5 | −476 | −828 | −1 257 | −1 016 |
| Tax | 0 | −0 | −0 | −0 | −0 |
| Net profit | −5 | −476 | −828 | −1 257 | −1 016 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 52 | 3 559 | 2 764 | 3 687 | 5 208 |
| Equity | −52 | 3 387 | 2 623 | 3 412 | 4 834 |
| Long-term debt | 62 | 62 | — | 62 | 62 |
| Short-term debt | 42 | 111 | 141 | 214 | 313 |
| Total debt | 104 | 173 | 141 | 275 | 375 |
EBITDA margin
-468.0%
This company
15.8%
Market median
-3062% vs market
20202024
Equity ratio
92.8%
This company
38.2%
Market median
+143% vs market
20202024
Return on equity
-21.0%
This company
18.4%
Market median
-214% vs market
20202024
Net profit margin
-491.1%
This company
8.1%
Market median
-6163% vs market
20202024
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
20202024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KH Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (4) | ||
KR Deputy auditor | Deputy auditor | 2017 – 2022 |
JA Deputy Member | Deputy Member | 2017 – 2021 |
MJ Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
AK Audit | Audit | 2017 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Chairperson | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Former (5) | ||
| Board of Directors | 2021 – 2025 | |
| Board of Directors | 2021 – 2025 | |
| Board of Directors | 2021 – 2025 | |
| Board of Directors | 2017 – 2021 | |
| Board of Directors | 2021 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Linio Biotech Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kari Ragnar Storgårds | Deputy auditor | 0 companies |
| Karita Hannele Reijonsaari | Chief Executive Officer | 0 companies |
| Jertta-Riina Anniina Uusmies | Deputy Member | 0 companies |
| Matti Jaakoppi Lehtipuu | Chief Executive Officer | 0 companies |
| Ari-Matti Korkeamäki | Audit | 0 companies |
| Tuija Päivi Keinonen | Board of Directors | 0 companies |
| Timo Juhani Lappi | Chairperson | 0 companies |
| Benoit Jacques Claude Chardon | Board of Directors | 0 companies |
| Laura Hannele Vartiainen | Board of Directors | 0 companies |
| Timo Jaakko Ylikomi | Board of Directors | 0 companies |
| Ilkka Einari Laurila | Board of Directors | 0 companies |
| Jaana Hannele Linna | Board of Directors | 0 companies |
| Ilkka Olavi Malka | Board of Directors | 0 companies |
| Didier Claude Leclercq | Board of Directors | 0 companies |
| Heikki Seppo Kupi | Board of Directors | 0 companies |